It is noteworthy that lenalidomide has a remarkable impact on the treatment of MDS associated with del(5q) as a single chromosomal alteration because it induces casein kinase 1 (Ck1α) degradation. This evidence concerns the gene CSNK1A1 and myelodysplastic syndrome.